DOI: 10.21276/sajp.2019.8.1.5

Pages: 23-29

Daunorubicin (DNR) is the potent broad-spectrum antineoplastic drugs widely used in treatment of cancers including acute myeloid leukemia and acute lymphocytic leukemia. But therapeutic use of DNR is limited due to cardiomyopathy. The renin-angiotensin system (RAS) plays crucial role in the development of cardiomyopathy. Changes of heart and increase duration of long-term survival with cardiac hypertrophy by inhibition of the RAS cascade and most effectively involve in the remodelling of the myocardium. Aliskiren (ALK) a recent drug of a direct inhibitor of the renin enzyme and keep safe cardiomyopathy in anthracycline - induced toxicity. Also the inhibition of the renin activity by aliskiren may effective and good approach in the safety of Anthracycline induced toxicity. The present study was focused to find the possible outcome of Aliskiren against DNR-induced cardiotoxicity. The acute model dose of 1.25 mg/kg DNR intraperitoneally in sixteen equal increasing doses induced cardiomyopathy in rats. DNR treatment remarkably increased the activities of serum creatine kinase (CK-MB), lactate dehydrogenase (LDH), cardiac cell caspase -3 catalase. ALK 100 mg/kg treatment safe the animal heart cell remarkably from rise in CK-MB, LDH and CAT. This study state that ALK save rats from DNR-induced cardiomyopathy.